Literature DB >> 27914007

Evaluation of 68Ga-labeled peptide tracer for detection of gelatinase expression after myocardial infarction in rat.

Max Kiugel1, Ville Kytö2,3, Tiina Saanijoki1, Heidi Liljenbäck1,4, Olli Metsälä1, Mia Ståhle1, Johanna Tuomela5, Xiang-Guo Li1,6, Pekka Saukko7, Juhani Knuuti1,8, Anne Roivainen1,4,8, Antti Saraste9,10,11.   

Abstract

BACKGROUND: Matrix metalloproteinases 2 and 9 (MMP-2/9) play a role in extracellular matrix remodeling after an ischemic myocardial injury. We evaluated 68Ga-DOTA-peptide targeting MMP-2/9 for the detection of gelatinase expression after myocardial infarction (MI) in rat.
METHODS: Rats were injected with 43 ± 7.7 MBq of 68Ga-DOTA-peptide targeting MMP-2/9 at 7 days (n = 7) or 4 weeks (n = 8) after permanent coronary ligation or sham operation (n = 5 at both time points) followed by positron emission tomography (PET). The left ventricle was cut in frozen sections for autoradiography and immunohistochemistry 30 minutes after tracer injection.
RESULTS: Immunohistochemical staining showed MMP-2 and MMP-9 expressing cells, CD31-positive endothelial cells, and CD68-positive macrophages in the infarcted myocardium. Autoradiography showed increased tracer uptake in the infarcted area both at 7 days and 4 weeks after MI (MI-to-remote area ratio 2.5 ± 0.46 and 3.1 ± 1.0, respectively). Tracer uptake in damaged tissue correlated with the amount of CD68-positive macrophages at 7 days after MI, and CD31-positive endothelial cells at 7 days and 4 weeks after MI. The tracer was rapidly metabolized, radioactivity in the blood exceeded that of the myocardium, and tracer accumulation in the heart was not detectable by in vivo PET.
CONCLUSIONS: 68Ga-DOTA-peptide targeting MMP-2/9 accumulates in the damaged rat myocardium after an ischemic injury, but tracer instability and slow clearance in vivo make it unsuitable for further evaluation.

Entities:  

Keywords:  Matrix metalloproteinase; myocardial infarction; positron emission tomography

Mesh:

Substances:

Year:  2016        PMID: 27914007     DOI: 10.1007/s12350-016-0744-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner.

Authors:  Jonathan A Disselhorst; Maarten Brom; Peter Laverman; Cornelius H Slump; Otto C Boerman; Wim J G Oyen; Martin Gotthardt; Eric P Visser
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

2.  Dimeric [(68)Ga]DOTA-RGD peptide targeting αvβ 3 integrin reveals extracellular matrix alterations after myocardial infarction.

Authors:  Max Kiugel; Ingrid Dijkgraaf; Ville Kytö; Semi Helin; Heidi Liljenbäck; Tiina Saanijoki; Cheng-Bin Yim; Vesa Oikonen; Pekka Saukko; Juhani Knuuti; Anne Roivainen; Antti Saraste
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

3.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.

Authors:  S Heymans; A Luttun; D Nuyens; G Theilmeier; E Creemers; L Moons; G D Dyspersin; J P Cleutjens; M Shipley; A Angellilo; M Levi; O Nübe; A Baker; E Keshet; F Lupu; J M Herbert; J F Smits; S D Shapiro; M Baes; M Borgers; D Collen; M J Daemen; P Carmeliet
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

4.  Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling.

Authors:  Haili Su; Francis G Spinale; Lawrence W Dobrucki; James Song; Jing Hua; Sarah Sweterlitsch; Donald P Dione; Patti Cavaliere; Conroy Chow; Brian N Bourke; Xiao-Yu Hu; Michael Azure; Padmaja Yalamanchili; Richard Liu; Edward H Cheesman; Simon Robinson; D Scott Edwards; Albert J Sinusas
Journal:  Circulation       Date:  2005-11-07       Impact factor: 29.690

5.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

Authors:  L E Rohde; A Ducharme; L H Arroyo; M Aikawa; G H Sukhova; A Lopez-Anaya; K F McClure; P G Mitchell; P Libby; R T Lee
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

6.  Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction.

Authors:  A Ducharme; S Frantz; M Aikawa; E Rabkin; M Lindsey; L E Rohde; F J Schoen; R A Kelly; Z Werb; P Libby; R T Lee
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

7.  Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction.

Authors:  Zakir H Sahul; Rupak Mukherjee; James Song; Jarod McAteer; Robert E Stroud; Donald P Dione; Lawrence Staib; Xenophon Papademetris; Lawrence W Dobrucki; James S Duncan; Francis G Spinale; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2011-04-19       Impact factor: 7.792

8.  Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.

Authors:  Tiina Ujula; Merja Huttunen; Pauliina Luoto; Hannu Peräkylä; Ilkka Simpura; Ian Wilson; Mathias Bergman; Anne Roivainen
Journal:  Bioconjug Chem       Date:  2010-09-15       Impact factor: 4.774

Review 9.  Membrane-associated matrix proteolysis and heart failure.

Authors:  Francis G Spinale; Joseph S Janicki; Michael R Zile
Journal:  Circ Res       Date:  2013-01-04       Impact factor: 17.367

10.  Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells.

Authors:  Po-Hsun Huang; Yung-Hsiang Chen; Chao-Hung Wang; Jia-Shiong Chen; Hsiao-Ya Tsai; Feng-Yen Lin; Wei-Yuh Lo; Tao-Cheng Wu; Masataka Sata; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-21       Impact factor: 8.311

View more
  5 in total

Review 1.  Emerging Tracers for Nuclear Cardiac PET Imaging.

Authors:  Dong-Yeon Kim; Sang-Geon Cho; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2018-05-08

2.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2018. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2019-01-02       Impact factor: 5.952

Review 3.  PET imaging in heart failure: the role of new tracers.

Authors:  Antti Saraste; Juhani Knuuti
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

4.  Evaluation of [68Ga]Ga-DOTA-TCTP-1 for the Detection of Metalloproteinase 2/9 Expression in Mouse Atherosclerotic Plaques.

Authors:  Max Kiugel; Sanna Hellberg; Meeri Käkelä; Heidi Liljenbäck; Tiina Saanijoki; Xiang-Guo Li; Johanna Tuomela; Juhani Knuuti; Antti Saraste; Anne Roivainen
Journal:  Molecules       Date:  2018-12-01       Impact factor: 4.411

Review 5.  Neutrophil degranulation and myocardial infarction.

Authors:  Nan Zhang; Xiahenazi Aiyasiding; Wen-Jing Li; Hai-Han Liao; Qi-Zhu Tang
Journal:  Cell Commun Signal       Date:  2022-04-11       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.